Company profile

Celox Medical

celoxmedical.comHeadquarters: United Kingdom
51-200 employeesHybrid (Product + Service)
Celox Medical logo

Primary focus

Development, clinical evaluation, and commercialization of patented haemostatic and advanced wound-care technologies.

Why it’s included

The company develops and manufactures chitosan-based hemostatic gauzes and granules, including CELOX Rapid, which is explicitly described as stopping severe bleeding from emergency life-threatening injuries within 60 seconds and is recommended by the US Committee on Tactical Combat Casualty Care, directly matching the topic's requirements for rapid, field-usable hemorrhage control at non-compressible sites.

Relevant capabilities

  • Chitosan-based hemostatic material development
  • Design and formulation of haemostatic products (granules, gauze, pads)
  • Product testing and performance evaluation
  • Clinical evaluation and evidence generation
  • Advanced wound dressing development
Commercial sectorTopical Hemostatic Agents & Dressings
Technology classesChitosan-based topical hemostatic dressings, Limb tourniquets for extremity hemorrhage control

Relevant commercial products

  • CELOX™ Gauze 5’ Z-Fold Gauze
  • CELOX Rapid
  • CELOX™ Rapid X-Ray Detectable 5’ Z-Fold Gauze – 3in x 5ft (7.6cm x 1.5m)
  • CELOXTM
  • CELOX Haemostat Device Family

← Back to what’s inside this report